Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Changes in Self-awareness
NCT07732166Phase 1Recruiting
- Sponsor
- Pontifical Catholic University of Rio de Janeiro
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in major depressive disorder (MDD), obsessive compulsive disorder (OCD) and anxiety disorder (2 arms), sponsored by Pontifical Catholic University of Rio de Janeiro. Primary endpoint: Changes in global metacognitive judgment using the Computerized Success-Failure Manipulation Paradigm at 1 week. Started Apr 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)obsessive compulsive disorder (OCD)anxiety disorder
Beyond the preview
Go deeper on NCT07732166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732166.